12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Grazax: Phase III data

A Phase III trial in about 1,500 patients with grass pollen-induced allergic rhinoconjunctivitis showed that grass AIT met the primary endpoint of improving combined rhinoconjunctivitis daily symptom and medication scores during the grass pollen season...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >